"We need to determine the long-term effect in animals, and we need to determine the optimal time window" when the VEGF nanofibers need to be administered, said Dr. Hsieh.

WSJ: Nanotechnology Holds Promise for Heart Patients

He added that our optimal "Disney age window" would be closing soon.

WSJ: The Price of Being Too Thrifty